Table 2.
Toxicities of the h-R3/RT and CDDP/RT groups (N = 104)
| Toxicities (RTOG Grade) | h-R3/RT (N = 52) [n (%)] | CDDP/RT (N = 52) [n (%)] | P Value* |
|---|---|---|---|
| WBC | 0.048* | ||
| (1&2) | 32 (61.5%) | 32 (61.5%) | |
| (3&4) | 1 (1.9%) | 7 (13.5%) | |
| PLT | 0.752 | ||
| (1&2) | 19 (36.5%) | 18 (34.6%) | |
| (3&4) | 1 (1.9%) | 2 (3.8%) | |
| HB | 0.499 | ||
| (1&2) | 27 (51.9%) | 26 (50%) | |
| (3&4) | 0 (0.00%) | 0 (0.00%) | |
| ALT | 0.294 | ||
| (1&2) | 10 (19.1%) | 8 (11.9%) | |
| (3&4) | 0 (0.00%) | 0 (0.00%) | |
| AST | 0.197 | ||
| (1&2) | 10 (19.2%) | 5 (9.6%) | |
| (3&4) | 0 (0.00%) | 0 (0.00%) | |
| GGT | 0.166 | ||
| (1&2) | 9 (17.3%) | 5 (9.6%) | |
| (3&4) | 0 (0.00%) | 0 (0.00%) | |
| Dermatitis | 0.445 | ||
| (1&2) | 33 (63.5%) | 44 (84.6%) | |
| (3&4) | 2 (3.8%) | 1 (1.9%) | |
| Rash | 0.248 | ||
| (1&2) | 5 (9.6%) | 3 (5.8%) | |
| (3&4) | 1 (1.9%) | 0 (0.00%) | |
| Mucositis | 0.093 | ||
| (1&2) | 21 (40.4%) | 26 (50%) | |
| (3&4) | 30 (57.7%) | 25 (48.1%) | |
| Taste change | 0.763 | ||
| yes | 46 (88.5%) | 47 (90.4%) | |
| no | 6 (11.5%) | 5 (9.6%) | |
| Vomit | 0.000* | ||
| only nausea | 12 (23.1%) | 2 (3.8%) | |
| nausea and vomit | 5 (9.6%) | 43 (78.8%) | |
| Weight loss | 0.249 | ||
| (1&2) | 26 (50.0%) | 30 (57.7%) | |
| (3&4) | 13 (25.0%) | 15 (28.8%) |
Abbreviations: RT radiotherapy, h-R3/RT nimotuzumab and radiotherapy, CDDP/RT cisplatin and radiotherapy. WBC white blood cell, PLT Platelets, HB hemoglobin, ALT alanine transaminase, AST glutamic-oxalacetic transaminease, GGT gamma glutamyl transpeptidase
*All p values were obtained by the paired rank sum test